News Hub | News Direct

PROMPERÚ Launches Campaign Inviting Peruvians to Celebrate Their Cultural Diversity

Promperu

In the latter half of the last century, composer Mario Cavagnaro emerged as an iconic figure, deeply enriching the country’s music. Among his most recognized songs is “Qué viva el Perú señores,” (Long live Peru, ladies and gentlemen) a gem of Creole music and a love letter to Peru. This beautiful piece, updated with new rhythms and sounds, is the chosen song for the video manifesto of the new campaign presented by the Commission for the Promotion of Peru for Export and Tourism (PROMPERÚ): “Peru, land of infinite gifts.” Performed by a Peruvian singer specializing in pop fusion and Andean music, and by an established cumbia band, the song's lyrics are illustrated by images showcasing invaluable heritage sites, renowned gastronomy, and cultural diversity. In this month of national celebrations, the campaign aims to foster pride and unity among Peruvians. Peru’s brand, driven by PROMPERÚ, invites the public to connect with Peru's cultural diversity, infinite wealth, and ancient wisdom—essential elements for building national identity and a better future. Uncover the campaign pieces here www.paisdedonesinfinitos.pe Peru Export and Tourism Promotion Board (PROMPERÚ). We are the government agency in charge of the development and implementation of global strategies to position Peru via the promotion of its image, touristic destinations, added value exports and inversions. Contact Details José Carlos Collazos jcollazos@promperu.gob.pe Company Website http://www.promperu.gob.pe

July 12, 2024 02:30 PM Eastern Daylight Time

First Phosphate Corp Reports Positive Drill Results at Bégin-Lamarche Project

First Phosphate Corp

First Phosphate Corp Chief Geologist Gilles Laverdiere joined Steve Darling from Proactive to discuss the latest results from the company's Bégin-Lamarche project in Quebec. The company has completed a 25,929-meter drill program ahead of schedule in April, with all samples now shipped to the lab for analysis. A 43-101 resource estimate will soon be initiated, followed by a Preliminary Economic Assessment. Both studies are expected to be completed by the end of fiscal Q4 2024. Laverdiere highlighted that significant phosphate layers were intersected in all but two holes continuously across the 3 km magnetic trend at Bégin-Lamarche. A total of 23 drill holes have been completed in the Phosphate Mountain Zone, with data from 20 drill holes showing grades over 10% P2O5, with widths ranging from 7 m to 99 m. The Phosphate Mountain Zone has been drilled for a total length of 250 m so far and is beginning to merge with the Northern Zone, where a 500 m thick phosphate mineralized envelope exists. This envelope has delineated up to five individual layers ranging from 60 m to 100 m in thickness, starting at the surface and continuing down to a depth of 300 m. The overall strike length of the Phosphate Mountain Zone and the Northern Zone is approximately 600 meters. Laverdiere expressed optimism about these results, emphasizing that they showcase the robust potential of the Bégin-Lamarche project. With the upcoming resource estimate and economic assessment, First Phosphate Corp aims to solidify its position as a key player in the phosphate mining sector. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 12, 2024 01:45 PM Eastern Daylight Time

Video

News Release

Chesapeake Bank Launches Real-Time Payments System for Trucking Sector

Chesapeake Financial Shares Inc

DJ Seeterlin, Chief Innovation and Strategy Officer, and Kevin Wood, Managing Director of Flexent at Chesapeake Bank, recently joined Steve Darling from Proactive to discuss an exciting new business initiative in the trucking sector. Chesapeake Bank, known for offering the Flexent program focusing on accounts receivable financing since 1995, has taken a significant step forward to address a pressing need in the industry. In 2023, recognizing the necessity for faster payment solutions for truck drivers—who often need immediate funds for expenses such as fuel and repairs—Chesapeake Bank acquired another company to develop a real-time payments system. This innovative system allows truck drivers to receive funds instantly upon load delivery and paperwork submission, effectively bypassing slower methods like ACH and expensive wire transfers. The initiative has already seen strong adoption, with 93% of truck drivers preferring instant payments. Chesapeake Bank has been a pioneer in adopting real-time payment technologies, being among the first 25 banks in the US to implement them in 2020. Their early involvement and proactive approach in the industry have enabled them to swiftly deploy these solutions, demonstrating their commitment to innovation and customer satisfaction. The new service is expected to significantly benefit the trucking sector by providing faster and more efficient payment options. Additionally, it is poised to enhance Chesapeake Bank's traditional receivables financing business, while also generating additional revenue through ancillary products. This initiative underscores Chesapeake Bank's dedication to meeting the evolving needs of its clients and advancing the financial services industry. The company emphasized the importance of this development, highlighting how the real-time payments system not only supports truck drivers in their day-to-day operations but also strengthens Chesapeake Bank's position as a leader in financial innovation. As the trucking industry continues to grow and evolve, Chesapeake Bank remains committed to providing cutting-edge solutions that drive success for their clients. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

July 12, 2024 01:43 PM Eastern Daylight Time

Video

ATFX's Strategic Meeting at the Chinese Embassy in Jordan Highlights Dedication to Regional Economic Development

500NewsWire

Hong kong, July 12, 2024 - ( 500NewsWire ) -- (ATFX is a leading global fintech broker with a local presence in 23 locations, including the Levant. Since setting up a team in the region, ATFX has been dedicated to expanding its brand influence in Jordan. A recent significant meeting at the Embassy of the People's Republic of China in the Hashemite Kingdom of Jordan highlighted ATFX's commitment. The meeting was attended by Joe Li, Chairman of ATFX; Siju Daniel, Chief Strategy Officer of ATFX and Ahmad Al Disi, Managing Director of ATFX Levant, along with Mr. Luo Wenjun, Counselor of the Chinese Embassy in Jordan. This high-profile event delved into ATFX's foreign investment strategies in the Hashemite Kingdom of Jordan and the broader Levant region, emphasizing its meticulously planned blueprint for prosperous development. The ATFX Group not only demonstrated its strong determination to deepen its presence in the region but also vividly illustrated its selfless dedication to promoting regional economic growth and cooperation through a series of innovative initiatives and localized strategies. In the coming period, ATFX will remain true to its original mission, continuing to race ahead in providing top-tier services to its clients, all while maintaining steady and orderly progress. Looking ahead, ATFX is committed to serving its global clients with enthusiasm, high-quality service, and highly efficient financial operations, enabling more people to enjoy premium, secure financial investment services, ultimately benefiting investors worldwide! About ATFX ATFX is a leading global fintech broker with a local presence in 23 locations and licenses from regulatory authorities, including the UK's FCA, Cypriot CySEC, UAE's SCA, Australian ASIC, and South African FSCA. With a strong commitment to customer satisfaction, innovative technology, and strict regulatory compliance, ATFX provides exceptional trading experiences to clients worldwide. For further information on ATFX, please visit the ATFX website: https://www.atfx.com. Contact Details ATFX sales.uk@atfx.com

July 12, 2024 01:38 PM Eastern Daylight Time

Image

Diversified Energy Announces Strategic Acquisition of High-Interest Texas Natural Gas Assets

Diversified Energy Company PLC

Diversified Energy Company CEO Rusty Hutson Jr. joined Steve Darling from Proactive to announce the conditional purchase and sale agreement for acquiring high-working interest, operated natural gas properties and related facilities located within eastern Texas from Crescent Pass Energy. The company expects to close the acquisition in the third quarter of 2024. These assets are contiguous with Diversified's existing East Texas assets and include approximately 170,000 acres of commercially attractive leasehold in both East Texas and the Freestone Trend. Hutson informed Proactive about the current net production of 38 MMcfepd (6 Mboepd), with low annual declines of around 9%. This acquisition boasts industry-leading corporate declines and capital intensity. Hutson highlighted the importance of low decline rates in managing annual production levels and securing long-term cash flows. He also emphasised the company's strategy of growth through acquisitions, focusing on assets that add value to shareholders. A notable aspect of this transaction was the use of shares from Diversified Energy's US listing as part of the purchase price, marking a significant step in leveraging the company's equity in future acquisitions. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

July 12, 2024 12:05 PM Eastern Daylight Time

Video

Attorney Moze Cowper Wins Oral Argument Against Hologic Inc. in BioZorb Litigation

Cowper Law

Massachusetts - July 12, 2024 - ( ThriveNewsWire ) - Cowper Law has successfully defeated a motion for summary judgment based on the learned intermediary doctrine involving the BioZorb medical device manufactured by Hologic, Inc. Moze Cowper, the managing partner of Cowper Law, argued and won the important motion in state court in Massachusetts. Defendant Hologic filed a motion for summary judgment based on the learned intermediary doctrine arguing that the implanting doctor still would have implanted the BioZorb device even knowing the risks of harm that the plaintiff alleged. The Court wrote: "[h]ere, although Hologic relies upon the fact Dr. Hughes is a licensed physician, that the plaintiff ‘cannot’ prove failure to warn caused the plaintiff's injury, and that the learned intermediary doctrine precludes plaintiff's claims, there are a plethora of material factual disputes including, but not limited to, the extent of the relationship between Hologic (and/or its officers/shareholders) and Dr. Hughes, knowledge of the risks involved with the device versus alternative, and any potential bias due to his relationship with Hologic (acknowledging as well that discovery is ongoing as related to claims not precluded by the learned intermediary doctrine)." Cowper Law, along with the Jinks Crow law firm, and Bailey Glasser have also filed 90+ lawsuits in federal court in Massachusetts. The case is captioned: Lyons v. Hologic Inc., Docket #2281CV04312. Contact Details Cowper Law Moze Cowper +1 310-750-7337 mcowper@cowperlaw.com Company Website https://cowperlaw.com/moze-cowper/

July 12, 2024 09:00 AM Eastern Daylight Time

Autonomix's Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Autonomix Medical (NASDAQ: AMIX) is a cutting-edge medical technology company developing targeted nerve therapies to revolutionize how diseases involving the peripheral nervous system are diagnosed and treated. The company's ongoing proof-of-concept (PoC) human clinical trial is evaluating the safety and efficacy of radiofrequency (RF) ablation in a transvascular approach to reduce pain associated with pancreatic cancer and, to date, has demonstrated extremely compelling results. If successful, Autonomix has the potential to dramatically impact patient well-being and improve quality of life, offering new hope for patients enduring pancreatic cancer pain. Key Trial Insights The initial phase of the clinical trial involved five lead in patients who underwent the procedure without complications or significant adverse events. Some 60% of these subjects experienced a significant reduction in pain, with a mean decrease of 6.33 points on the Visual Analogue Scale (VAS) pain scale, dropping from a baseline of 8.0 to 1.67 just seven days post-procedure. Patients also reported quick pain relief, with some feeling better as soon as one day after the procedure. A detailed look at the data should provide Autonomix with important insight into optimizing the procedure, particularly the catheter entry point, where three of the five patients who benefited with meaningful pain reduction had femoral access to the catheter and the two that did not respond had brachial access. The primary objective of this PoC trial is to assess the success rate of ablating relevant nerves to mitigate pain in patients with pancreatic cancer using radiofrequency ablation. Secondary objectives include evaluating device- and procedure-related adverse events up to six weeks post-procedure, changes in pain levels and improvements in quality of life from pre- to post-procedure. Autonomix is proceeding with enrolling an additional 20 subjects to participate in the study and expects to complete enrollment by the end of 2024. The company expects to report topline results from all 20 subjects in the first half of next year. Clinical Trial Testimonials According to Autonomix, patients in the responder group reported substantial improvements in their quality of life. On average, these patients noted a 78% enhancement in how they viewed their overall health and a 45% boost in how they viewed their life quality, within seven days of the procedure. This rapid relief is crucial for individuals facing end-of-life situations due to advanced pancreatic cancer, offering them a better quality of life during their remaining time. Patient testimonial s further emphasize the impact of the procedure. Before the procedure, patients can struggle with debilitating pain, which affects their ability to sleep, eat and perform daily activities. Post-procedure, patients experienced immediate, life-changing pain relief and could sleep on their back, return to work and attend social events. Additionally, one patient stated they no longer needed painkillers, and experienced significant improvements in overall health and quality of life. This transformation underscores the procedure's potential to greatly enhance the lives of patients suffering from pancreatic cancer pain. Technical Approach And Future Plans Autonomix's technology aims to improve upon current pain management methods, which often rely on systemic drugs like opioids or invasive procedures that can have severe side effects. Autonomix’s catheter-based system is also designed to detect and ablate pain-associated neural signals more accurately. While the current trial focuses on pancreatic cancer-related pain, Autonomix also plans to explore other indications in the future based on these promising results. A New Dawn In Pain Management Autonomix’s innovative approach to pain management for pancreatic cancer patients is showing encouraging potential. The initial success of its PoC clinical trial offers a glimpse into a possible future where patients suffering from severe pain can find relief through precise and effective medical technology. As the company gathers more data, the medical community awaits its results, which could revolutionize pain management far beyond just pancreatic cancer pain and have applications across all pain and diseases of the peripheral nervous system. Featured photo by Alexander Grey on Unsplash Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

July 12, 2024 08:45 AM Eastern Daylight Time

Image

SEALMINER: Bitdeer's R&D Roadmap Promises Innovation And Transparency In Bitcoin Mining

Benzinga

By Gerelyn Terzo, Benzinga In the spirit of driving greater transparency in the Bitcoin mining industry, Bitdeer has introduced its highly anticipated research & development (R&D) technology roadmap for its SEALMINER Bitcoin mining rig. The company is targeting the mass production of innovative power efficiency 5J/TH chips by Q4 2025 through strategic investments in research and development (R&D). The motivations for SEALMINER are multi-pronged. As a Bitcoin mining leader, Bitdeer believes that transparent advancements in mining rig development are critical to miners’ success. As a result, miners can gain greater clarity into the entire Bitcoin hardware lifecycle, including technological advancements and timely deliveries of Bitcoin mining machines as well as a view into the data analytics of mining machine capabilities, investor buying behaviors, and equipment inventory. “We believe that the financial models of Bitcoin miners are significantly impacted by price uncertainty. If these two aspects of transparency are not addressed, the mining community is more likely to suffer severe financial losses,” said Bitdeer Chief Business Officer Linghui Kong. Bitdeer’s SEALMINER Roadmap Revealed The first milestone on Bitdeer’s SEALMINER roadmap is dubbed SEAL01, which involves the release of chip energy efficiency 18.1J/TH, announced in Q1 2024. That technology has already been integrated into SEALMINER A1, the company’s maiden mining machine. Next is SEAL02, with an impressive energy efficiency of 14J/TH, reflecting wall-mount energy consumption in the range of 15J/TH-16.5J/TH. The upgrade, whose launch is expected in Q3 2024, represents Bitdeer’s second-generation SEALMINER mining machine. SEAL02 is on track for mass-production and deliveries by year-end 2024. The introduction of the SEAL03 machine improves energy efficiency to 10J/TH, with a wall-mount power consumption of between 11J/TH and 12J/TH. SEAL03 represents Bitdeer’s third-generation SEALMINER mining machine and is poised for mass production and deliveries in Q2 2025. Lastly, the SEAL04 machine, with an energy efficiency of a low 5J/TH, has an expected launch date of Q2 2025. The optimization of the mining machine's wall-mount power consumption is expected to be in the range of 5.5J/TH to 6J/TH. This fourth-generation SEALMINER mining machine is planned for mass-production with expected delivery starting in Q4 2025. Bitdeer has a team of top engineers, representing 25% of the company’s total headcount, committed to the R&D process across specific chip technology applications, including ASIC design, algorithm development and platform architecture, as well as hardware and software design. Bitdeer Grows By Leaps And Bounds Bitdeer is having a groundbreaking year in which it has entered its next phase of growth and development. In addition to its transparent SEALMINER roadmap, the company has ushered in a $150 million private placement by leading stablecoin provider Tether International, and has bolstered its ASIC chip capabilities through the recent acquisition of fabless crypto ASIC design company Desiweminer. With Q1 revenue of $119.5 million, an annual increase of 64.6 %, Bitdeer has momentum on its side. The company’s innovative ASIC technology led to a 65% increase in the number of bitcoins mined in the first three months of the year as Bitdeer inches closer toward a quarterly threshold of 1,000 bitcoins. Investors who are bullish about the ASIC technology of the future, including a sustainable approach to the power-intensive process of Bitcoin mining that aims to reduce the industry’s carbon footprint and silence critics, could look into Bitdeer, during one of the most exciting times in Bitcoin history. Featured photo by TheDigitalArtist on Pixabay Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

July 12, 2024 08:30 AM Eastern Daylight Time

Image

News Release

Prenetics Global (NASDAQ: PRE): Bending Biotech with Beckham

RazorPitch - PRE

As the global population ages and the prevalence of chronic diseases rises, there is an increasing demand for innovative solutions that can enhance prevention, diagnosis, and treatment. The health sciences industry is undergoing a significant transformation, thanks to advances in genomics, personalized medicine, and early detection technology. One major example is the global cancer diagnostics market, which was valued at USD 19.5 billion in 2023 and is expected to reach USD 54.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.1% during the forecast period. In this dynamic landscape, one company has been making waves recently: Prenetics Global Limited (NASDAQ: PRE). PRE: A Key Player in Health Innovation Prenetics Global Limited (NASDAQ: PRE), a genomics-driven health sciences company, is making significant strides in the sector. The company operates through three primary units: CircleDNA, Insighta, and ACT Genomics, each contributing significantly to its mission of improving lives through science. CircleDNA: Offers one of the most comprehensive consumer DNA tests available, utilizing whole exome sequencing. This test provides extensive insights into an individual's genetic predispositions, promoting proactive health measures and personalized wellness plans. Insighta: A $200 million joint venture with renowned scientist Professor Dennis Lo, focuses on developing multi-cancer early detection technologies. The goal is to create a simple blood test that can detect multiple types of cancer at early stages, making early detection more accessible and affordable globally. ACT Genomics: The first Asia-based company to achieve FDA clearance for comprehensive genomic profiling of solid tumors through its ACTOnco test. This milestone enables personalized cancer treatments based on detailed genetic profiles, significantly enhancing treatment efficacy. Financial Performance and Strategic Milestones Prenetics Global has demonstrated robust financial performance. On June 19, 2024, the company announced its unaudited financial results for the first quarter ending March 31, 2024. The company reported revenue from continuing operations of $6.4 million, a notable 30.2% increase compared to the first quarter of 2023. Gross profit from continuing operations surged to $3.8 million, reflecting a 159.8% increase from the previous year. Adjusted EBITDA from continuing operations improved by 55.9%, resulting in a loss of $4.1 million. Additionally, the company maintained a robust cash position with $86.6 million in cash and other short-term assets as of March 31, 2024. Insighta held a cash balance of $79.8 million on the same date. Danny Yeung, Chief Executive Officer and Co-Founder of PRE, remarked, "The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit. These results demonstrate firm governance of our financial position with no debt, supported by a resilient and talented team." Strategic Focus on the US Market Prenetics Global is shifting towards the US consumer healthcare market to expand access to their health solutions. This move includes establishing dual headquarters to capitalize on new opportunities both domestically and globally. Yeung emphasized, "As we enter the second half of 2024, we are making significant strides in our strategic realignment with a keen focus on the consumer healthcare market in the USA. Our purpose remains dedicated to our science-first approach in our pivot to consumer healthcare to broaden accessibility to science-based health and wellness." Recent Appointments and Board Changes On July 1, 2024, PRE announced the addition of Kathryn M. Henry and David Vanderveen as independent directors to the company's Board of Directors. CEO Danny Yeung noted, "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." Partnership with David Beckham On July 11, 2024, Prenetics Global announced a new partnership with former international footballer, entrepreneur, and philanthropist David Beckham. Beckham has become a strategic investor in the business, and together with PRE, they will co-found a new health and wellness brand, IM8. Beckham expressed his excitement about the partnership, saying, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That’s why I am excited to be working with PRE - a company that is dedicated to innovative, world-leading scientific advancements in health - as a co-founding partner and ambassador for IM8.” Danny Yeung highlighted the significance of this collaboration, stating, "This partnership with David marks a transformative era for PRE in global health innovation and wellness. David epitomizes the values of discipline, teamwork, and health, aligning perfectly with PRE's core principles. Working closely with David these past months, I've been consistently inspired by his vision for accessible health for all. His passion and commitment are truly extraordinary. With IM8, we have a unique opportunity to contribute meaningfully to the consumer health and wellness industry." Conclusion Prenetics Global Limited (NASDAQ: PRE) is making significant progress in the genomics and health sciences sectors, with a strong focus on cancer prevention, detection, and treatment. The company's recent financial performance, strategic focus on the US market, promising clinical trials, and high-profile partnership with David Beckham highlight its potential for continued growth and innovation. Investors interested in genomics and health sciences may want to keep a close eye on PRE. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of content related to PRE. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

July 12, 2024 06:00 AM Eastern Daylight Time

All Industries

PROMPERÚ Launches Campaign Inviting Peruvians to Celebrate Their Cultural Diversity

First Phosphate Corp Reports Positive Drill Results at Bégin-Lamarche Project

Chesapeake Bank Launches Real-Time Payments System for Trucking Sector

ATFX's Strategic Meeting at the Chinese Embassy in Jordan Highlights Dedication to Regional Economic Development

Diversified Energy Announces Strategic Acquisition of High-Interest Texas Natural Gas Assets

Attorney Moze Cowper Wins Oral Argument Against Hologic Inc. in BioZorb Litigation

Autonomix's Trial Results Show Meaningful Reduction In Pain For Patients Suffering From Pancreatic Cancer

SEALMINER: Bitdeer's R&D Roadmap Promises Innovation And Transparency In Bitcoin Mining

Prenetics Global (NASDAQ: PRE): Bending Biotech with Beckham